Hanwha Pharm ordeded to distribute Livial

Published: 2003-11-28 06:57:00

Updated: 2003-11-28 06:57:00

The Seoul District Court accepted on November 25 the request of Hanwha Pharm to seek an injunction trial against the Korea Food and Drug Administration to invalidate cancellation of the product license of Livial, a first choice comprehensive treatment for the relief of climacteric symptoms in pos...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK